COMPARE · Reviewed July 29, 2026
ADUS vs OSCR
Verdict: Side-by-side breakdown using the Bull Rankings model. ADUS scored 75.1, OSCR scored 74.4 — ADUS leads.
Compare another set
ADUS
Addus HomeCare Corporation
75.1
$119.13 · $2.2B
fundamentals as of
Score gap
0.7
ADUS leads
OSCR
Oscar Health, Inc.
74.4
$30.57 · $9.2B
fundamentals as of
The model, pillar by pillar (0–100 each)
ADUS
stronger →← stronger
OSCR
57
Qualityreturns · margins · balance sheet
41
96
Growthrevenue & earnings expansion
100
77
Valuevaluation vs sector peers
100
OSCR is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ADUS
OSCR
$137mC
FCF
$2.8bB
+19.6%B+
Rev
+27.5%A-
0.12B+
D/E
0.29B
22.0xB+
P/E
—
1.11B+
PEG
—
—
P/S
0.7xA
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ADUS
OSCR
9% below
Price vs fair valuelower is cheaper
76% below
~3%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-22%/yr
+4%
1-yr DCF upside
+216%
+10%
5-yr DCF upside
+309%
+18%
10-yr DCF upside
+478%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
The companies
ADUSAddus HomeCare Corporation
Why now
Medical Care Facilities · market cap $2.2b. 4% off the 52-week high of $124.44. Revenue growing +20%, comfortably above the S&P median. 13 sell-side analysts rate this a Buy with a mean 1-yr target of $133.00 (implying +12% upside).
Moat
FCF converts 138% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
OSCROscar Health, Inc.
Why now
Healthcare Plans · market cap $9.2b. 8% off the 52-week high of $33.10. Revenue growing +27% — in hypergrowth territory. 10 sell-side analysts rate this a Hold with a mean 1-yr target of $25.20 (implying -18% upside).
Moat
Turnaround / out-of-favor name — GAAP-unprofitable for now, so the durability case is forward-looking: it rests on a recovery (margin normalization, a cyclical upturn or restructuring) or an un-monetized asset (IP / network effects / first-mover position) rather than on current reported results.
Risk
Currently unprofitable (margin -0.3%) — path to GAAP profitability is the core thesis risk. Beta 2.34 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. ROE -3% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.